SCHEMBL714537

SCHEMBL714537

CNC1Cc2ccccc2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.53
IDO1 P14902 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
DRD2 P14416 2/20 0.46
DRD3 P35462 2/20 0.46
DRD4 P21917 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
GRIN2B Q13224 1/20 0.45
SLC6A2 P23975 8/20 0.45
SLC6A4 P31645 8/20 0.45
SLC6A3 Q01959 7/20 0.45
CYP2D6 P10635 5/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
KCNH2 Q12809 3/20 0.44
CYP2C19 P33261 2/20 0.44
CYP3A4 P08684 1/20 0.44
PDPK1 O15530 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1027335 0.97 SIGMAR1 (0.52) SIGMAR1IDO1CA1CA2DRD2
Hydrochloric Acid SCHEMBL10462131 0.91 SIGMAR1 (0.47) SIGMAR1IDO1CA1CA2DRD2
SCHEMBL4606877 0.84 MTNR1A (0.61) SIGMAR1CA1CA2DRD2DRD3
SCHEMBL29599386 0.84 MTNR1A (0.61) SIGMAR1CA1CA2DRD2DRD3
SCHEMBL823057 0.84 MTNR1A (0.61) SIGMAR1CA1CA2DRD2DRD3
SCHEMBL823055 0.84 MTNR1A (0.61) SIGMAR1CA1CA2DRD2DRD3
Hydrochloric Acid SCHEMBL1026136 0.83 MTNR1A (0.59) SIGMAR1CA1CA2DRD2DRD3
SCHEMBL10513266 0.83 SIGMAR1 (0.45) SIGMAR1DRD2DRD3DRD4SLC6A2
Hydrochloric Acid SCHEMBL7430755 0.83 MTNR1A (0.59) SIGMAR1CA1CA2DRD2DRD3
Hydrochloric Acid SCHEMBL10463559 0.81 SIGMAR1 (0.44) SIGMAR1DRD2DRD3DRD4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4782252-B2 2011-09-28 JP claimed
EP-0738149-A4 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF TEVA PHARMA (IL) 1999-10-27 EP claimed
EP-0738149-A1 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1996-10-23 EP claimed
WO-1995018617-A1 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1995-07-13 WO claimed
CN-115348959-B Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity GT增益治疗股份有限公司 2025-01-07 CN disclosed
CN-118804911-A Acrylamide compound NRG治疗有限公司 2024-10-18 CN disclosed
WO-2024141998-A1 METHOD OF TREATING TAUOPATHIES GT GAIN THERAPEUTICS SA (CH) 2024-07-04 WO disclosed
US-20240190809-A1 THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS AWAKN LS EUROPE HOLDINGS LIMITED (IE) 2024-06-13 US disclosed
EP-4337316-A1 THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS Awakn Ls Europe Holdings Limited (IE) 2024-03-20 EP disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 US disclosed
WO-2023081967-A1 COMPOUNDS AND USES THEREFOR THE UNIVERSITY OF WESTERN AUSTRALIA (AU) 2023-05-19 WO disclosed
EP-0447292-A1 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application SYNTHELABO (FR) 1991-09-18 EP disclosed
US-5006561-A Indane sulfonamide anti-arrhythmic agents and use PFIZER INC. (US) 1991-04-09 US disclosed
EP-0286277-B1 ANTIARRYTHMIC AGENTS Pfizer Limited (GB) 1990-06-20 EP disclosed
CN-1038449-A Antiarrhythmics PFIZER LTD (GB) 1990-01-03 CN disclosed
US-4829071-A Quinolyl substituted indane sulfonamides and their use as anti-arrhythmic agents PFIZER INC. (US) 1989-05-09 US disclosed
EP-0286277-A1 Antiarrythmic agents Pfizer Limited (GB) 1988-10-12 EP disclosed
EP-0286278-A1 Indanamine derivatives useful as antiarrhythmic agents Pfizer Limited (GB) 1988-10-12 EP disclosed
EP-0144235-A2 N6-(1- and 2-benzocycloalkyl) adenosines, pharmaceutical compositions comprising the same and a process for the production thereof WARNER-LAMBERT COMPANY (US) 1985-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190809-A1 THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS AADAT, PNMT, SLC1A2 SIGMAR1 197/4885IDO1 228/4885CA1 3455/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 SIGMAR1 4233/4885IDO1 714/4885CA1 4756/4885
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 SIGMAR1 3090/4885IDO1 981/4885CA1 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.